Jingjin Gao is a distinguished Principal Scientist at Bristol Myers Squibb, where he leverages over 20 years of extensive experience in pharmaceutical molecular biology to drive innovative solutions in oncology and immunology. As a Subject Matter Expert (SME) in genomics within the Translational Development team,...
Jingjin Gao is a distinguished Principal Scientist at Bristol Myers Squibb, where he leverages over 20 years of extensive experience in pharmaceutical molecular biology to drive innovative solutions in oncology and immunology. As a Subject Matter Expert (SME) in genomics within the Translational Development team, Jingjin plays a pivotal role in shaping and executing biomarker strategies across ten clinical programs, guiding projects from First-In-Human (FIH) trials through dose-escalation and into dose expansion phases. His deep expertise in clinical biomarker assay development and validation is complemented by a robust understanding of Companion Diagnostics (CDx) and In Vitro Diagnostics (IVD), making him an invaluable asset in the realm of precision medicine.
Jingjin's leadership in clinical biomarker operations encompasses vendor oversight and central lab management, ensuring that all aspects of biomarker strategy implementation are executed with precision and efficiency. His proficiency in sample logistics, coupled with advanced techniques such as Laser Capture Microdissection and Immunohistochemistry (IHC), enables him to optimize the collection and analysis of critical biological samples, facilitating the identification of actionable insights that drive clinical decision-making.
In addition to his technical skills, Jingjin excels in project management, adeptly navigating the complexities of clinical trials while fostering collaboration among cross-functional teams. His strategic vision and commitment to advancing cancer immunology and cell therapy are evident in his contributions to the development of cutting-edge therapies that aim to improve patient outcomes. Through his work, Jingjin Gao exemplifies the integration of scientific rigor and innovative thinking, positioning Bristol Myers Squibb at the forefront of transformative cancer treatment.
